A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
Latest Information Update: 24 Jun 2024
At a glance
- Drugs Trospium chloride/xanomeline (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms ADEPT-1
- Sponsors Karuna Therapeutics
- 18 Jun 2024 Planned End Date changed from 1 Apr 2025 to 30 Apr 2025.
- 18 Jun 2024 Planned primary completion date changed from 1 Mar 2025 to 31 Mar 2025.
- 22 Feb 2024 This study has been Completed in Germany, According to European Clinical Trials Database record.